drugset / Trial / NCT03592277

Vitamin C & Thiamine to Treat Sepsis and Septic Shock

NCT03592277

Phase 2 Completed 120 enrolled Trinity Health Of New England
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Investigators propose to investigate the use of IV vitamins B1 and C in a randomized, double-blinded, prospective trial to determine if these medications decrease mortality rates in patients with severe sepsis or septic shock.

Timeline

Start
2018-09-14
Primary completion
2021-02-22
Completion
2021-02-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Thiamine Other / unclassified 200 mg Intravenous
Subject Vitamin C Other / unclassified 1.5 g Intravenous